Quick Answer: Why May Weight-Loss Maintenance Matter More Than the Initial Result?
For obesity, the scientifically important outcome is not only how much weight is lost, but whether the reduction can be maintained over time.
The strongest tirzepatide evidence for this question comes from the SURMOUNT-4 randomized withdrawal trial. Participants first received tirzepatide for 36 weeks and achieved a mean body-weight reduction of 20.9%. They were then randomized either to continue tirzepatide or switch to placebo for another 52 weeks.
Those who continued tirzepatide lost an additional 5.5% of body weight from Week 36 to Week 88, whereas those switched to placebo regained 14.0%. At Week 88, 89.5% of participants continuing tirzepatide had maintained at least 80% of their initial weight loss, compared with 16.6% after switching to placebo. The overall mean reduction from baseline to Week 88 was 25.3% with continued tirzepatide versus 9.9% after withdrawal.
More recent post-hoc analysis adds another important layer: greater weight regain after tirzepatide withdrawal was associated with greater reversal of improvements in waist circumference, systolic blood pressure, non-HDL cholesterol, HbA1c and fasting insulin.
This does not prove that every person requires indefinite tirzepatide treatment. It does show why a short-term mindset can be misleading when discussing obesity pharmacotherapy.
The modern question is increasingly:
Key Takeaways
- Weight loss and weight-loss maintenance are related but distinct treatment outcomes.
- SURMOUNT-4 directly tested what happened when tirzepatide treatment was continued versus withdrawn after substantial initial weight reduction.
- Participants had lost an average of 20.9% of body weight after 36 weeks of tirzepatide treatment before randomization.
- Over the following 52 weeks, continued tirzepatide produced an additional 5.5% weight reduction, while placebo withdrawal was associated with 14.0% weight regain.
- 89.5% of participants continuing tirzepatide maintained at least 80% of their initial weight loss versus 16.6% after switching to placebo.
- Withdrawal does not mean that everyone regains all lost weight, but substantial regain was common in the SURMOUNT-4 population.
- A 2025/2026 post-hoc analysis found that greater weight regain after withdrawal was associated with greater reversal of several cardiometabolic improvements.
- Three-year SURMOUNT-1 data demonstrate that continued tirzepatide can produce sustained weight reduction over a much longer period than the initial weight-loss phase.
- Current obesity guidelines increasingly frame obesity as a chronic, relapsing disease requiring long-term management rather than a short intervention.
- Maintenance should therefore be considered an outcome in its own right, not merely the period after “successful” treatment.
- Long-term treatment decisions should be individualized and clinically supervised rather than based on an assumption that treatment must automatically continue or automatically stop.
- For long-term residents in Nha Trang, the relevant mindset is sustainable health management rather than repeatedly starting and stopping short-term weight-loss interventions.
Introduction: The Most Important Question May Come After the Weight Comes Off
Weight-loss conversations often follow a simple storyline.
Start treatment.
Lose weight.
Reach the target.
Stop.
Move on.
That model is intuitive.
It is also increasingly difficult to reconcile with the biology and clinical evidence surrounding obesity.
Obesity is now widely described in contemporary clinical guidance as a chronic, progressive and relapsing disease.
That changes the meaning of treatment success.
If a person loses substantial weight but subsequently regains much of it, the initial response was real — but the long-term outcome may be less impressive.
This is why maintenance deserves its own scientific conversation.
For tirzepatide, that conversation became particularly important after SURMOUNT-4.
What Is Weight-Loss Maintenance?
Weight-loss maintenance is not simply “still weighing less than baseline.”
In clinical research, maintenance can mean several related things:
- preventing substantial regain after initial weight reduction;
- preserving improvements in waist circumference;
- maintaining metabolic improvements;
- maintaining improvements in obesity-related complications;
- and sustaining the health benefits associated with lower adiposity.
This distinction matters because a person could technically remain below their original body weight while still regaining a substantial portion of the weight they intentionally lost.
Therefore:
Maintenance = How much of that change persisted?
SURMOUNT-4 Was Designed to Ask the Maintenance Question
SURMOUNT-4 is particularly useful because it was not simply another trial asking whether tirzepatide produces weight loss.
It was a randomized withdrawal trial.
The study enrolled adults with obesity or overweight without diabetes.
Participants first received open-label tirzepatide for 36 weeks.
After that initial period, participants who had completed the lead-in were randomized into two groups:
- continue tirzepatide;
- or switch to placebo.
The double-blind randomized period then continued for another 52 weeks.
This design created a direct experimental question:
That is much closer to a maintenance question than a conventional weight-loss trial.
The Initial 36 Weeks Were Already a Major Weight-Loss Phase
Before randomization, participants had already experienced substantial weight reduction.
The mean body-weight reduction after 36 weeks of tirzepatide was:
This is important because the maintenance phase did not begin with people who had lost only a small amount of weight.
The trial therefore asked what happened after clinically meaningful weight reduction had already occurred.
That makes SURMOUNT-4 particularly relevant to the real-world question that often follows a successful initial response:
“What happens if treatment is stopped now?”
What Happened When Tirzepatide Was Continued?
Participants who continued their maximum tolerated tirzepatide dose during the randomized withdrawal period did not simply remain at exactly the same weight.
They experienced an additional mean weight reduction of approximately:
from Week 36 to Week 88.
The overall mean reduction from baseline to Week 88 was approximately:
This is an important distinction.
Maintenance in this study was not simply “preventing regain.”
Continued treatment was associated with further weight reduction while maintaining the previous loss.
What Happened After Tirzepatide Withdrawal?
The placebo-switch group showed a very different trajectory.
From Week 36 to Week 88, participants who switched from tirzepatide to placebo experienced a mean:
relative to their Week 36 weight.
Importantly, this did not mean every participant returned completely to their starting weight.
It means that, on average, substantial weight regain occurred after treatment withdrawal.
This distinction prevents two opposite mistakes.
The first mistake is:
“Stopping tirzepatide always causes complete weight regain.”
The trial does not demonstrate that.
The second mistake is:
“Once the weight is lost, stopping treatment generally preserves the result.”
SURMOUNT-4 does not support that interpretation either.
The 80% Maintenance Threshold Is Particularly Informative
The investigators also examined whether participants maintained at least 80% of the weight they had lost during the initial 36-week period.
The results were striking:
| Outcome at Week 88 | Continued Tirzepatide | Switched to Placebo |
|---|---|---|
| Maintained ≥80% of initial weight loss | 89.5% | 16.6% |
| Mean weight change during maintenance period | −5.5% | +14.0% |
| Overall mean change from baseline | −25.3% | −9.9% |
The contrast strongly supports the importance of continued treatment for maintaining the weight reduction achieved in this particular study population.
Why This Changes the Way We Think About Obesity Treatment
If obesity were simply an acute condition caused by a temporary behavioral problem, a short intervention followed by permanent discontinuation would make intuitive sense.
But chronic disease treatment often works differently.
Consider the conceptual difference:
| Short-Term Mindset | Chronic-Disease Mindset |
|---|---|
| Lose weight | Reduce adiposity and health risk |
| Reach target | Maintain clinically meaningful improvement |
| Stop treatment | Reassess long-term treatment needs |
| Measure scale weight | Measure weight plus complications and metabolic health |
| Treatment is a phase | Treatment may be part of ongoing disease management |
Current obesity guidelines increasingly use the second framework. The 2025 Canadian clinical practice guideline update explicitly supports long-term use of obesity pharmacotherapy for sustained weight loss and maintenance, while the 2025 AACE consensus describes obesity/adiposity-based chronic disease as requiring long-term treatment and care.
Weight Regain Is Not Merely a Cosmetic Problem
A common misconception is that weight regain is important only because people dislike seeing the number on the scale rise again.
That is too narrow.
Adiposity is biologically connected to multiple metabolic and cardiometabolic pathways.
Therefore, the consequences of weight regain may extend beyond body weight itself.
This question was examined in a more recent post-hoc analysis of SURMOUNT-4.
Newer Evidence: What Happened to Cardiometabolic Improvements During Regain?
The 2025/2026 post-hoc analysis divided participants who discontinued tirzepatide according to the proportion of their lost weight that they regained.
The analysis found that greater weight regain was associated with greater reversal of several improvements observed during the initial tirzepatide treatment period.
Across increasing categories of weight regain, mean increases in waist circumference became progressively larger:
- approximately 0.8 cm with less than 25% weight regain;
- approximately 5.4 cm with 25% to less than 50% regain;
- approximately 10.1 cm with 50% to less than 75% regain;
- approximately 14.7 cm with 75% or greater regain.
Systolic blood pressure, non-HDL cholesterol, HbA1c and fasting insulin also showed greater reversal with greater weight regain.
This does not prove that weight regain directly caused every individual metabolic change.
It does, however, strengthen the argument that maintenance is not simply an aesthetic endpoint.
The Chronic-Disease Mindset: Treat the Disease, Not Just the Scale
The phrase “weight-loss drug” can create an incomplete mental model.
It implies that the drug’s job ends once weight has fallen.
A chronic-disease framework asks a different question:
What treatment strategy produces durable improvement in the disease and its complications?
This is why contemporary guidance increasingly emphasizes:
- long-term treatment;
- risk reduction;
- obesity-related complications;
- metabolic health;
- person-centered care;
- and ongoing reassessment.
The 2025 AACE consensus specifically emphasizes optimizing health rather than focusing only on weight reduction or BMI.
The 2026 ADA Obesity Association standards similarly frame obesity pharmacotherapy as part of a comprehensive care plan and emphasize sustained weight reduction and improved clinical outcomes when medications are combined with lifestyle interventions.
Three Years of Tirzepatide Adds Another Piece to the Maintenance Story
SURMOUNT-1 provides a different but complementary perspective.
Rather than asking what happens immediately after withdrawal, the three-year analysis examined continued tirzepatide treatment in people with obesity and prediabetes.
At 176 weeks, mean body-weight changes were approximately:
- −12.3% with 5 mg;
- −18.7% with 10 mg;
- −19.7% with 15 mg;
- compared with −1.3% with placebo.
The same study also reported substantially lower progression to type 2 diabetes during the treatment period.
These data demonstrate that long-term treatment can sustain clinically meaningful weight reduction over approximately three years.
It is important not to confuse this study with SURMOUNT-4.
SURMOUNT-1 primarily informs us about long-term continued treatment.
SURMOUNT-4 informs us about what happened after withdrawal following initial weight reduction.
Together, they provide a more complete maintenance picture.
Maintenance Is Not the Same as “Never Change Treatment”
A chronic-disease mindset should not be confused with a rigid rule that everyone must remain on the same medication indefinitely.
That conclusion would go beyond the evidence.
Long-term management can involve:
- continuing treatment;
- adjusting treatment;
- changing treatment;
- monitoring response;
- addressing adverse effects;
- reassessing obesity-related complications;
- and considering alternative strategies when clinically appropriate.
The central idea is not:
“Never stop.”
It is:
“Do not assume that reaching an initial weight target automatically means the underlying chronic disease no longer requires management.”
Why Weight Regain Can Be Biologically Plausible
Weight regulation is not a simple mathematical equation in which a person permanently “uses up” excess body fat and then remains at the new weight automatically.
Body weight is regulated by interacting systems involving:
- appetite;
- satiety;
- energy expenditure;
- neuroendocrine signaling;
- adipose tissue biology;
- behavior;
- environment;
- and metabolic adaptation.
Pharmacological treatment can modify some of these pathways while it is active.
When treatment is withdrawn, the biological environment changes again.
SURMOUNT-4 provides clinical evidence consistent with that broader biological model: withdrawal was followed by substantial average weight regain in a population that had previously responded well to tirzepatide.
Why “I Reached My Goal Weight” Is an Incomplete Endpoint
Imagine two hypothetical people.
Person A loses 20 kg and remains near the new weight for several years.
Person B loses 20 kg but regains 15 kg during the following year.
Both experienced the same initial weight loss.
But their long-term treatment outcomes are clearly different.
This is why maintenance deserves independent attention.
Maintenance is a trajectory.
Maintenance Should Include More Than Body Weight
A chronic-disease approach evaluates multiple outcomes.
| Domain | Maintenance Question |
|---|---|
| Body weight | Is clinically meaningful weight reduction being sustained? |
| Waist circumference | Is central adiposity remaining improved? |
| Glycemia | Are glycemic improvements maintained? |
| Blood pressure | Are cardiometabolic improvements sustained? |
| Lipids | Are favorable lipid changes maintained? |
| Physical function | Is mobility and physical capacity preserved? |
| Treatment tolerability | Can the long-term strategy be tolerated and sustained? |
| Quality of life | Does treatment continue to support the person’s health goals? |
The Nha Trang Long-Term Resident Lens
Nha Trang is an interesting environment for a maintenance-focused conversation because many international residents are not visiting for a two-week holiday.
Long-stay residents may build a lifestyle around the city for months or years.
That creates a fundamentally different health-management problem.
The relevant question may not be:
“How much weight can I lose before my next trip?”
It may be:
“What health strategy can I realistically sustain while living here long term?”
That means considering:
- long-term access to qualified healthcare;
- continuity of clinical monitoring;
- changes in lifestyle and activity;
- travel between Vietnam and other countries;
- dietary changes over time;
- treatment tolerability;
- and what happens if treatment is interrupted.
For a long-term resident, a treatment plan that works for eight weeks but becomes impossible to sustain later may be less useful than a strategy designed around long-term continuity.
Travel and Continuity Are Part of the Maintenance Question
International residents frequently move between countries.
That introduces practical continuity questions that are easy to overlook during the initial weight-loss phase.
Examples include:
- Will treatment remain available during travel?
- Can medical monitoring continue across borders?
- Will the same clinical team be available for follow-up?
- What happens if treatment is interrupted?
- Is the person relying on a product that is not consistently regulated or approved in the destination country?
These are not pharmacological efficacy questions.
They are treatment-continuity questions.
For chronic disease management, they can be clinically relevant.
The Injection Pen Is a Delivery Format, Not a Maintenance Strategy
An injection pen can make a medication easier to handle as a delivery format.
But the device itself does not solve the maintenance problem.
A pen does not determine:
- whether treatment should continue;
- how long treatment should last;
- what clinical outcomes should be monitored;
- how adverse effects should be managed;
- or whether a person remains an appropriate candidate for pharmacotherapy.
Those are clinical management questions.
Therefore, it is important not to confuse:
with
Long-term treatment strategy
Why Stopping Treatment Is a Research Question — Not a Marketing Talking Point
There is a tendency in the commercial weight-loss market to frame discontinuation as either a failure or a success.
Scientific evidence is more nuanced.
The appropriate question is what happens to clinically meaningful outcomes after withdrawal.
SURMOUNT-4 gives us one answer for its specific population and design:
Withdrawal was associated with substantial average weight regain compared with continued tirzepatide.
It does not establish that every patient should remain on treatment forever.
It does establish that withdrawal is not biologically neutral.
What Current Guidelines Say About Long-Term Treatment
The chronic-disease perspective is not unique to tirzepatide.
The 2025 Canadian clinical practice guideline update explicitly supports long-term use of obesity pharmacotherapy for sustained weight loss and maintenance of weight loss.
The 2025 AACE consensus describes obesity/adiposity-based chronic disease as complex and chronic, requiring long-term treatment and care.
More recent expert guidance also gives a strong recommendation for continuing obesity medications during the weight-maintenance phase.
This represents an important conceptual shift from the older “diet until goal weight” model.
Maintenance Does Not Mean Ignoring Lifestyle
A common false dichotomy is:
Medication or lifestyle.
Modern obesity care generally does not use that framework.
Pharmacotherapy can be combined with:
- nutrition strategies;
- physical activity;
- resistance training;
- sleep optimization;
- behavioral interventions;
- management of obesity-related complications;
- and ongoing clinical monitoring.
The 2025 Canadian guideline explicitly places pharmacotherapy alongside health behavior changes, while the 2026 ADA standards describe obesity medication as part of a comprehensive care plan.
The objective is not to make medication the entire treatment strategy.
The objective is to create a sustainable treatment system.
What Maintenance Research Still Does Not Tell Us
Despite increasingly strong evidence, important questions remain.
- How long should an individual patient remain on tirzepatide?
- Can some patients successfully transition to another long-term strategy?
- What predicts successful discontinuation?
- Can lower-intensity maintenance strategies preserve benefits for selected patients?
- How should treatment be individualized after major improvements in obesity-related complications?
- What is the optimal maintenance strategy for people with different obesity phenotypes?
- How do maintenance strategies affect muscle, bone and physical function over many years?
SURMOUNT-4 was not designed to answer all of these questions.
It tested a specific randomized withdrawal scenario.
That distinction matters when translating trial findings into broader clinical practice.
The 2026 Evidence Base Is Moving Toward Maintenance as a Primary Outcome
Recent systematic evidence is also moving beyond the traditional “weight-loss trial” framework.
A 2026 systematic review and meta-analysis specifically examined anti-obesity medications for long-term weight maintenance after initial weight loss.
The emergence of this research question itself reflects a broader change in obesity science:
That is particularly relevant for therapies capable of producing substantial initial weight reduction.
Expert Insight #1: The First Year Can Be the Beginning, Not the End
Expert Insight: A successful initial response to an anti-obesity medication does not automatically mean the disease has been permanently resolved. SURMOUNT-4 demonstrates why maintenance deserves separate consideration: participants who had already lost approximately 21% of body weight experienced markedly different trajectories depending on whether tirzepatide was continued or withdrawn.
Expert Insight #2: Maintenance Is About Health, Not Just Weight
Expert Insight: The most sophisticated maintenance strategy is not necessarily the one that keeps the scale at exactly one number. It is the strategy that sustainably controls adiposity while supporting metabolic health, physical function, treatment tolerability and quality of life. The newer SURMOUNT-4 post-hoc analysis strengthens this perspective because greater weight regain was accompanied by greater reversal of several cardiometabolic improvements.
Statistics & Evidence Snapshot
| Finding | Evidence | Interpretation |
|---|---|---|
| SURMOUNT-4 lead-in | −20.9% mean body weight at Week 36 | Large initial response before maintenance phase |
| Continued tirzepatide | −5.5% from Week 36 to 88 | Weight reduction continued |
| Withdrawal group | +14.0% from Week 36 to 88 | Substantial average weight regain |
| ≥80% initial weight loss maintained | 89.5% continued vs 16.6% placebo | Large maintenance difference |
| Overall Week 88 change | −25.3% continued vs −9.9% withdrawal | Long-term trajectories diverged substantially |
| Three-year SURMOUNT-1 | −12.3% to −19.7% at 176 weeks depending on dose | Sustained long-term treatment effect |
| Post-hoc withdrawal analysis | Greater regain associated with greater reversal of several cardiometabolic improvements | Maintenance may matter beyond body weight |
Frequently Asked Questions
Because substantial initial weight loss can be followed by weight regain after treatment withdrawal. SURMOUNT-4 showed markedly better maintenance when tirzepatide was continued.
After 36 weeks of tirzepatide and approximately 20.9% mean weight loss, participants switched to placebo regained an average of 14.0% of body weight over the following 52 weeks.
Participants continuing tirzepatide experienced an additional mean 5.5% reduction in body weight during the 52-week randomized period.
No. The study showed substantial average regain, not universal complete regain. Individual trajectories varied.
At Week 88, 89.5% of participants continuing tirzepatide maintained at least 80% of their initial weight loss compared with 16.6% after switching to placebo.
A post-hoc SURMOUNT-4 analysis found that greater weight regain was associated with greater reversal of improvements in waist circumference, systolic blood pressure, non-HDL cholesterol, HbA1c and fasting insulin.
No. It demonstrates the effect of continuing versus withdrawing treatment in the studied population and design. It does not establish that every individual must remain on the medication indefinitely.
Current major clinical guidance increasingly describes obesity or adiposity-based chronic disease as chronic, progressive and relapsing, supporting long-term management rather than assuming a short treatment course is sufficient.
No. Long-term management may involve reassessment, adjustment or changes in therapy depending on clinical response, tolerability, complications and patient preferences.
A weight-loss mindset focuses on reaching a target number. A chronic-disease mindset focuses on maintaining improvements in adiposity, metabolic health, complications, function and quality of life over time.
Three-year SURMOUNT-1 data showed sustained mean weight reductions at 176 weeks, ranging from approximately 12.3% to 19.7% across the studied tirzepatide doses in participants with obesity and prediabetes.
Maintenance is relevant whenever substantial weight reduction is clinically meaningful. The appropriate treatment threshold and goals depend on adiposity, complications, health risks and individual circumstances.
Lifestyle measures remain important, but SURMOUNT-4 demonstrates that lifestyle support alone did not prevent substantial average regain in the withdrawal group under the trial conditions. This does not mean lifestyle interventions are ineffective; it highlights the complexity of maintaining pharmacologically assisted weight loss.
Long-term residents may need a health strategy that remains practical across months or years, including continuity of clinical care, travel, lifestyle changes and treatment availability. This makes sustainability more relevant than a short-term weight-loss target.
The pen is a delivery format. Maintenance depends on the underlying therapy and broader clinical management, not on the physical device itself.
Depending on the clinical situation, monitoring may include body weight, waist circumference, metabolic markers, obesity-related complications, treatment tolerability, nutritional status, physical function and quality of life.
The major lesson is that substantial initial weight loss does not guarantee durable maintenance after treatment withdrawal. Continued treatment produced a markedly different trajectory from switching to placebo.
Related Articles
- Vietnam Peptides Knowledge Hub: Peptide Research & Education
- Peptide FAQ: Research, Storage and Usage Questions
- Peptide Products for Recovery, Longevity & Performance Research
- Personalized Peptide Plans for Recovery, Fat Loss & Longevity Goals
Related Research Products
Premium Tirzepatide 20mg Injection Pen
A research-oriented injection-pen format centered on tirzepatide. The maintenance evidence discussed in this article comes from published clinical trials and should not be interpreted as evidence for the efficacy, safety or maintenance performance of any specific research-product formulation.
Retatrutide 20mg Injection Pen
A separate investigational multi-receptor metabolic research peptide. Retatrutide should not be treated as interchangeable with tirzepatide because its pharmacology and clinical evidence base are different.
Fat Loss Peptide Plan
Explore the Fat Loss Peptide Plan for a broader educational framework around metabolic and body-composition research. This resource is educational and research-focused and does not replace individualized medical care.
Scientific References
- Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. PMID: 38078870. DOI: 10.1001/jama.2023.24945.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387:205-216. PMID: 35658024. DOI: 10.1056/NEJMoa2206038.
- Garvey WT, et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med. 2024. PMID: 39536238.
- Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial. 2026. PMID: 41284285.
- Pedersen SD, Manjoo P, Dash S, et al. Pharmacotherapy for obesity management in adults: 2025 clinical practice guideline update. CMAJ. 2025;197(27):E797-E809. PMID: 40789597. DOI: 10.1503/cmaj.250502.
- Nadolsky K, Garvey WT, Agarwal M, et al. American Association of Clinical Endocrinology Consensus Statement: Algorithm for the Evaluation and Treatment of Adults With Obesity/Adiposity-Based Chronic Disease — 2025 Update. Endocr Pract. 2025;31(11):1351-1394. PMID: 40956256. DOI: 10.1016/j.eprac.2025.07.017.
- American Diabetes Association Professional Practice Committee for Obesity. Pharmacologic treatment of obesity in adults: Standards of care in overweight and obesity. BMJ Open Diabetes Res Care. 2026;13(Suppl 1):e005729. PMID: 41529914. DOI: 10.1136/bmjdrc-2025-005729.
- Joint TOS/OMA/OAC expert guidance statement on the pharmacological management of United States adults with overweight or obesity using the GRADE approach. 2026. PMID: 41859682.
- AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. Gastroenterology. 2022. PMID: 36273831.
- Efficacy and Safety of Anti-Obesity Medications for Weight Loss Maintenance in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Diabetes Obes Metab. 2026. PMID: 42426361. DOI: 10.1111/dom.71083.
- Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes—2025. Diabetes Care. 2025;48(Suppl 1):S167-S180. PMID: 39651976. DOI: 10.2337/dc25-S008.
- Introduction and methodology: Standards of Care in Overweight and Obesity—2025. BMJ Open Diabetes Res Care. 2025;13(Suppl 1):e004928. PMID: 40379435.
Conclusion
The most important lesson from modern tirzepatide research may not be how much weight people can lose.
It may be what happens after the initial result has been achieved.
SURMOUNT-4 provides unusually direct evidence because it deliberately tested treatment withdrawal.
After 36 weeks of tirzepatide, participants had lost approximately 20.9% of body weight.
When treatment continued, they lost an additional 5.5% on average during the following year.
When treatment was withdrawn, they regained approximately 14.0% on average.
And while 89.5% of participants continuing tirzepatide maintained at least 80% of their initial weight loss, only 16.6% of those switched to placebo achieved that threshold.
More recent analysis suggests that weight regain can also coincide with reversal of several cardiometabolic improvements.
This is why maintenance should not be treated as an afterthought.
The chronic-disease perspective is more realistic:
Maintaining health improvements is another.
That does not mean every person should remain on tirzepatide forever.
It means treatment decisions should be based on the long-term management of obesity and its complications rather than an arbitrary assumption that treatment must end when a target number appears on the scale.
For long-term residents of Nha Trang, this distinction is particularly relevant.
A sustainable health strategy needs to work not only during the first successful months, but also through travel, lifestyle changes, changing activity levels and the realities of living in one place for years.
The scientifically mature question is therefore not:
“How quickly can I lose the weight?”
It is:
“How can clinically meaningful improvements in adiposity and health be maintained over the long term?”
Quick Answer
Core Questions: What happens when tirzepatide is stopped? How much weight is regained after tirzepatide withdrawal? Does continuing tirzepatide maintain weight loss? What did SURMOUNT-4 show about maintenance? Is obesity a chronic disease? Does weight regain reverse metabolic improvements? Should weight-loss treatment be viewed as long-term management?
Core Statistics: SURMOUNT-4: −20.9% mean weight reduction after 36 weeks; −5.5% additional change with continued tirzepatide vs +14.0% regain after withdrawal; 89.5% vs 16.6% maintained at least 80% of initial weight loss.
Long-Term Evidence: Three-year SURMOUNT-1 data showed sustained weight reduction with continued tirzepatide through 176 weeks.
Maintenance Concept: Weight-loss maintenance should be evaluated as an independent treatment outcome rather than assumed to occur automatically after initial weight reduction.
Chronic-Disease Framework: Obesity is chronic, progressive and relapsing; long-term management may include pharmacotherapy, nutrition, physical activity, behavioral interventions and monitoring of obesity-related complications.
Important Qualification: SURMOUNT-4 does not prove that every person requires indefinite tirzepatide treatment. It demonstrates the consequences of continued treatment versus withdrawal in the studied population and trial design.
Expat Lens: Long-term international residents in Nha Trang who need sustainable treatment continuity rather than short-term weight-loss interventions.